NRF2 maintains redox balance via ME1 and NRF2 inhibitor synergizes with venetoclax in NPM1-mutated acute myeloid leukemia
Overall, our findings provide new insight into the therapeutic potential of targeting NRF2 and guide the development of innovative combination therapies in NPM1-mutated AML.
Authors
- Qiaoling Xiao
- Fangfang Jin (ORCID: https://orcid.org/0000-0002-2255-1423)
- Xingyu Wei (ORCID: https://orcid.org/0000-0001-6603-2636)
- X Y Chen (ORCID: https://orcid.org/0009-0001-8407-8774)
- Jun Ren (ORCID: https://orcid.org/0000-0002-3098-9767)
- Jing Yang (ORCID: https://orcid.org/0000-0002-3289-3048)
- Ling Zhang (ORCID: https://orcid.org/0000-0003-1097-6034)
- Nan Wu (ORCID: https://orcid.org/0000-0002-3531-1656)
- Ziwei Li (ORCID: https://orcid.org/0000-0002-9087-4881)
- Zihao Yuan (ORCID: https://orcid.org/0000-0002-9735-0394)
- Wen Zhao
- Yongcan Liu
- Lisha Tang
- Jiayuan Hu
- Shu Yan
Institutions
- Fuling Center Hospital of Chongqing (CN)
Publication Details
- Journal
- Cancer & Metabolism
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1186/s40170-025-00401-6
- Citations
- 2
- Primary Topic
- Genomics, phytochemicals, and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- National Natural Science Foundation of China